Allergan Announces FDA Approval of Juvederm® Gel Family of Products for the Treatment of Facial Wrinkles and Folds; 'Next Generation' Smooth Gel, Non-Animal Dermal Fillers Offer Natural, Long-Lasting Results

Business Wire, June 5, 2006

IRVINE, Calif. -- Allergan, Inc. (NYSE:AGN), the makers of BOTOX(R) Cosmetic (Botulinum Toxin Type A), today announced the U.S. Food and Drug Administration (FDA)'s approval of the Juvederm(R) gel family of products, a 'next generation' of hyaluronic acid dermal fillers that provide a smooth, long-lasting correction of facial wrinkles and folds. Juvederm(R)'s proprietary, technologically advanced formulations result in a smooth, natural look and contain the highest concentration of non-animal and cross-linked hyaluronic acid of any dermal filler currently available. These unique attributes provide optimal results with a single treatment in the majority of patients and deliver sustained results for up to six months or longer.

"We are excited to offer physicians and patients Juvederm(R), the next generation smooth gel hyaluronic acid formulations approved by the FDA as an important new option for the correction of facial wrinkles and folds," said Scott M. Whitcup, M.D., Allergan's Executive Vice President, Research and Development. "Juvederm(R)'s unique gel formulation is easy to inject and provides a long-lasting clinical result."

With the FDA approval, Juvederm(R) joins BOTOX(R) Cosmetic and an array of other dermal filler and skin care treatments in Allergan's facial aesthetics portfolio, which provides patients and physicians with the most comprehensive total facial rejuvenation product offering available.

Juvederm(R) is natural, biodegradable and currently the only approved hyaluronic acid dermal filler that has demonstrated its safety and effectiveness in patients of all skin types and colors. It also is the only hyaluronic acid dermal filler developed using a proprietary, technologically advanced manufacturing process that results in a malleable smooth gel that flows easily into the skin, creating a smooth, natural look and feel. All other currently approved hyaluronic acid dermal fillers utilize a gel particle suspension formulation. These gel particles can be visibly seen as opposed to the smoother formulation used in Juvederm(R) in the linked demonstration video.

"It is very exciting to have a new facial rejuvenation tool with the unique qualities of Juvederm(R) that we can now offer to our patients. Our clinical investigation found Juvederm(R) to be a smooth-flowing injection that provides our patients with a natural appearing result. The new formulation of hyaluronic acid offers physicians a high level of control for facial contouring," said Gary Monheit, M.D., Total Skin & Beauty Dermatology Center, P.C.; Associate Clinical Professor, Department of Dermatology and Ophthalmology, University of Alabama at Birmingham; and Juvederm(R) Clinical Investigator.

The Juvederm(R) family of products offers the highest concentration of cross-linked hyaluronic acid available in a dermal filler, which results in a long duration of effect and may be attributed to the majority of patients not requiring touch-ups following their initial treatment. The smooth consistency of the Juvederm(R) formula also may help to minimize the discomfort that can sometimes occur during the injection procedure.

The FDA approved three different formulations for Juvederm(R) providing physicians with the flexibility to tailor each treatment to the particular needs of the patient. The three product formulations include: Juvederm(R) 24HV, a highly cross-linked formulation for more versatility in contouring and volumizing of facial wrinkles and folds; Juvederm(R) 30HV, a more highly cross-linked robust formulation for volumizing and correction of deeper folds and wrinkles; and Juvederm(R) 30, a highly cross-linked formulation for subtle correction of facial wrinkles and folds.

Our presentation of the products, including the package and accessories, is currently being finalized and availability dates are expected to be announced later in 2006. Physicians and consumers are encouraged to visit www.JuvedermComingSoon.com to receive updates on product availability.

Hyaluronic acid dermal fillers represent the fastest growing non-invasive aesthetic procedure in the United States and BOTOX(R) Cosmetic has been the number one physician-administered, non-surgical cosmetic procedure in the United States since 2002, according to the American Society of Aesthetic Plastic Surgeons. Occurring naturally in the body, hyaluronic acid is a natural complex sugar found in all living organisms and creates volume and elasticity in the skin. Juvederm(R) adds volume to facial wrinkles, such as nasolabial folds (the folds running from the sides of the bottom of the nose to the outer corners of the mouth). BOTOX(R) Cosmetic works differently -- by relaxing the dominant frown muscles between the eyebrows (the glabellar area). This allows the two vertical lines between the brows, often referred to as the "11," to temporarily diminish in appearance. Like BOTOX(R), which has been available for more than 16 years and is currently approved to treat 20 different medical conditions in more than 75 countries around the world, hyaluronic acid treats multiple medical conditions, including those associated with the eye and the knee, and has been used for more than 20 years. The same formulation of BOTOX(R) was approved by the FDA in 2002 as BOTOX(R) Cosmetic for the temporary improvement in the appearance of moderate to severe frown lines between the brows in people 18 to 65 years of age.